The latest announcement is out from Impedimed Limited ( (AU:IPD) ).
Impedimed Limited has announced the issuance of 815,481 fully paid ordinary shares to its executives as part of their remuneration for the quarter ended March 31, 2025. This move is part of the company’s Executive Share Plan and reflects its strategy to align executive compensation with company performance, potentially impacting its financial structure and stakeholder interests.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on developing and providing innovative solutions for the measurement of fluid status and tissue composition. The company’s primary products are used in healthcare settings to assist in the management of conditions such as lymphedema and heart failure.
YTD Price Performance: -50.0%
Average Trading Volume: 72,592
Technical Sentiment Signal: Buy
Current Market Cap: $44.05M
Find detailed analytics on IPD stock on TipRanks’ Stock Analysis page.